title: [Seniority of neurobladder and effectiveness of a first intradetrusor injection of botulinum toxin].
abstract: Intradetrusor injection of botulinum toxin is one of the second-line therapy of neurologenic detrusor overactivity.
  
  
  OBJECTIVE
  In 26% to 66% of the cases, intradetrusor injection of botulinum toxin is inefficient in order to reduce overactive bladder symptoms and/or overactive detrusor. The objective of this study is to determine whether it exists a link between the efficacy of the first IDBT and the length of neurological detrusor overactivity symptoms.
  
  
  METHODS
  Retrospective study on 79 patients which have a first intradetrusor injection of botulinum toxin between January 2001 and December 2013. Inclusion criteria were patients older than 18 and having neurological detrusor overactivity.
  
  
  RESULTS
  There is no significant difference of intradetrusor injection of botulinum toxin efficacy according to duration of urinary symptoms in the general neurologigal population (multiple sclerosis, spinal cord injury, spinal cord compression, ischemic pathology, infectious pathology) with the mean age being 46 years. On the contrary, the length of evolution of neurological detrusor overactivity symptoms before the intradetrusor botox injection therapy and the efficiency of the first intradetrusor injection of botulinum toxin seem to be correlated with negative results in patients with multiple sclerosis.
  
  
  CONCLUSIONS
  The duration of urinary symptoms is a predictive factor of primary failure of intradetrusor injection of botulinum toxin in multiple sclerosis patients, in univariate analysis.
authors.affiliation: Sorbonne universités, UPMC université Paris 06, GRC 01, Green, group of clinical research in neuro-urology, 75005 Paris, France; Service de neuro-urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France. Electronic address: marlene_lct@hotmail.com.
authors.forename: M
authors.initials: M
authors.lastname: Lacout
authors.affiliation: Sorbonne universités, UPMC université Paris 06, GRC 01, Green, group of clinical research in neuro-urology, 75005 Paris, France; Service de neuro-urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Guinet-Lacoste
authors.affiliation: Sorbonne universités, UPMC université Paris 06, GRC 01, Green, group of clinical research in neuro-urology, 75005 Paris, France; Service de neuro-urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Popoff
authors.affiliation: Sorbonne universités, UPMC université Paris 06, GRC 01, Green, group of clinical research in neuro-urology, 75005 Paris, France; Service de neuro-urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Verollet
authors.affiliation: Sorbonne universités, UPMC université Paris 06, GRC 01, Green, group of clinical research in neuro-urology, 75005 Paris, France; Service de neuro-urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Lebreton
authors.affiliation: Sorbonne universités, UPMC université Paris 06, GRC 01, Green, group of clinical research in neuro-urology, 75005 Paris, France; Service de neuro-urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Amarenco
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000328:Adult; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A
keywords: Botulinum toxin; Hyperactivité vésicale; Neurogenic bladder; Neurovessie; Overactive bladder; Toxine botulique